Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...
In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy, forthe prevention of LRTD caused by RSV in older adults aged 60+ years. This was the first RSV vaccine for older adults to be approved ...
The EU on Friday authorized the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...
The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...
U.S. health officials on Friday recommended RSV vaccinations for moms-to-be, a second new option to protect newborns from ...
New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...
Updated COVID-19 vaccines are being rolled out in the U.S., aimed at targeting the latest, prevalent variants of the disease.
Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...
The shot will help shield newborns from RSV in the early months of life, when they're especially vulnerable to severe illness ...
Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...
